Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720831 | 0.80 | MAPT (0.55) | MAPK1TSHRMAPTCYP1A2ALDH1A1 | |
| SCHEMBL16002975 | 0.80 | ALDH1A1 (0.55) | MAPK1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL13212656 | 0.79 | MEN1 (0.60) | MEN1TP53KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL16238665 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2AMAPK1TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28576459 | 0.79 | CA2 (0.59) | TSHRSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28582423 | 0.79 | CA2 (0.59) | TSHRSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28576462 | 0.79 | CA2 (0.59) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL8256259 | 0.78 | MEN1 (0.58) | MEN1TP53KMT2AMAPK1AKR1C3 | |
| SCHEMBL4305149 | 0.78 | MEN1 (0.82) | MEN1TP53KMT2AAKR1C3TSHR | |
| SCHEMBL2202342 | 0.78 | MEN1 (0.82) | MEN1TP53KMT2AAKR1C3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398771-B1 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-07-29 | — | — | EP | claimed |
| EP-2398771-B1 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MEN1 4853/4885TP53 4743/4885KMT2A 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.